HTA Database - Search Results

Sort by Relevance

Search Results [15895 Hits] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Antibiotic prophylaxis for lower extremity wound debridement in the outpatient setting
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Point of care vascular ultrasound
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Early mobilization to reduce medical inpatient length of stay and adverse
2020	Andalusian Health Technology Assessment Area (AETSA)	[Effectiveness and safety of the macrobiotic diet]
2020	European Network for Health Technology Assessment (EUnetHTA)	Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
2020	European Network for Health Technology Assessment (EUnetHTA)	Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity
2020	European Network for Health Technology Assessment (EUnetHTA)	Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)
2020	European Network for Health Technology Assessment (EUnetHTA)	Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older
2020	European Network for Health Technology Assessment (EUnetHTA)	Cefiderocol for the treatment of infections due to aerobic gram-negative bacteria in adult patients with limited treatment options
2020	European Network for Health Technology Assessment (EUnetHTA)	Glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy
2020	European Network for Health Technology Assessment (EUnetHTA)	Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB)
2020	European Network for Health Technology Assessment (EUnetHTA)	Remdesivir or the treatment of COVID-19. PICO and evidence gaps
2020	European Network for Health Technology Assessment (EUnetHTA)	Remdesivir for the treatment of COVID-19
2020	European Network for Health Technology Assessment (EUnetHTA)	Dexamethasone for the treatment of hospitalised patients with COVID-19
2020	European Network for Health Technology Assessment (EUnetHTA)	Hypoglossal nerve stimulation systems for treatment of obstructive sleep apnea
2020	European Network for Health Technology Assessment (EUnetHTA)	Biodegradable rectum spacers to reduce toxicity for prostate cancer
2020	European Network for Health Technology Assessment (EUnetHTA)	The 24-hour blood pressure measurement device Mobil-O-Graph® with the built-in algorithm ARCSolver® to measure arterial stiffness for the optimization of hypertension treatment and assessment of cardiovascular disease risk
2020	European Network for Health Technology Assessment (EUnetHTA)	Lung cancer screening in risk groups
2020	European Network for Health Technology Assessment (EUnetHTA)	Rapid collaborative review on the current role of antibody tests for novel coronavirus SARS-COV-2 in the management of the pandemic
2020	European Network for Health Technology Assessment (EUnetHTA)	Rapid collaborative review on the diagnostic accuracy of molecular methods that detect the presence of SARS-COV-2 virus in people with suspected COVID-19
2020	European Network for Health Technology Assessment (EUnetHTA)	Lopinavir and ritonavir for the treatment of COVID-19
2020	Swiss Federal Office of Public Health (FOPH)	Vitamin D testing
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: protecting health care workers' (HCW) families at home
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: corticosteroids for hospitalized patients
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: prophylactic use of hydroxychloroquine (HCQ)
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: treatment with hydroxychloroquine (HCQ)
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: infectivity of patients who have recovered from disease
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Cytokine adsorption for treatment of COVID-19 disease
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: decontamination and reprocessing of personal protective equipment (PPE)
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Transmission of respiratory infections via showers
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Remdesivir for treatment of COVID-19 disease
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: sedation-ventilation liberation of COVID+ patients
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: surgical masks and filtering face piece respirators (FFR) for health care providers
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: point-of-care (POC) testing
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: antibiotic management in ambulatory patients
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: temperature screening for healthcare personnel
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: criteria for discharging patients from inpatient care
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: high flow nasal cannula (HFNC)/non-invasive positive pressure ventilation (NIPPV) indications
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: proning considerations for patients on HFNC or BIPAP
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: criteria for advising home care patients to return to the hospital
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: surge triage for suspected influenza-like illness
2020	Malaysian Health Technology Assessment (MaHTAS)	Pre-dialysis education programme (PDEP)
2020	Malaysian Health Technology Assessment (MaHTAS)	Diagnostic approaches to solitary pulmonary nodule (SPN)
2020	Malaysian Health Technology Assessment (MaHTAS)	Cinacalcet for the treatment of secondary hyperparathyroidism in end stage renal failure and economic evaluation
2020	Malaysian Health Technology Assessment (MaHTAS)	Influenza vaccination for the elderly and economic evaluation
2020	Malaysian Health Technology Assessment (MaHTAS)	Intravenous iron for iron deficiency anaemia
2020	Malaysian Health Technology Assessment (MaHTAS)	Programmatic management of latent tuberculosis infection
2020	Malaysian Health Technology Assessment (MaHTAS)	Automatic guided vehicles (AGVs) for transportation of food and materials in hospitals
2020	Malaysian Health Technology Assessment (MaHTAS)	Digital dental impression
2020	Malaysian Health Technology Assessment (MaHTAS)	Biocompatible peritoneal dialysis (PD) solution
2020	Malaysian Health Technology Assessment (MaHTAS)	Prophylactic anticoagulation in ambulatory cancer patients
2020	Malaysian Health Technology Assessment (MaHTAS)	Antifibrotic for treatment of idiopathic pulmonary fibrosis
2020	Malaysian Health Technology Assessment (MaHTAS)	Needleless Vacutainer system for blood collection
2020	Andalusian Health Technology Assessment Area (AETSA)	[C-Reactive Protein point-of-care testing (CRP-POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Spyglass® cholangiopancreatoscopy for biliary and pancreatic diseases]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angioplasty with stent placement in patients with carotid artery disease]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Precice® intramedullary nail system, with external remote controller, for limb length discrepancy]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Fetal neurosonography in suspected central nervous system abnormalities]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Renal replacement therapies in acute kidney failure]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intravascular ultrasound in coronary artery disease]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Human papilloma virus (HPV) vaccine in patients with HPV lesions or infection]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Parenteral infusion pump during general hospital ward]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angioplasty with stent placement in patients with deep vein thrombosis]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Digital tomosynthesis for breast cancer]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Target next generation sequencing-based gene panels in tumors of unknown origin]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Platelet rich plasma in musculoskeletal conditions]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Image-guided radiation therapy in liver and lung tumors]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Volumetric modulated arc therapy in patients with lung cancer, prostate cancer, high-risk gliomas and tumors in head and neck]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pegvaliase in phenylketonuria]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Digital dermatoscopy for dysplastic nevi]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Somatostatin analogs with lutetium-177 in neuroendocrine tumors]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Dupilumab in atopic dermatitis not adequately controlled with atopical therapy]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ustekinumab in Crohn’s disease]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ozone therapy]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Radiofrequency ablation in benign bone tumors]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Endoscopic spine surgery for disc disease and lumbar spinal stenosis]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Endoscopic full-thickness resection of colorectal lesions]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Virtual colonoscopy for colorectal cancer screening in patients with diverticular disease]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intra-arterial chemotherapy for retinoblastoma]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intranasal esketamine for severe resistant major depression]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intrathecal baclofen pump in spastic patients]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Endometrial microbiome test in assisted reproduction]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Eculizumab in the management of paroxysmal nocturnal hemoglobinuria and atypical hemolytic-uremic syndrome]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Migalastat for Fabry disease]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Advice on a potential candidate for conditional inclusion of rhPTH 1-84 (Natpar®) in chronic hypoparathyroidism
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice concerning romosozumab (Evenity®) for the treatment of severe osteoporosis
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of amikacin liposome inhalation suspension (Arikayce® liposomal) for the treatment of NTM lung infections
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment - extension of further conditions for nintedanib (Ofev®)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab (Pola-BR) for the treatment of r/r DLBCL
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of tafamidis (Vyndaqel®) for the treatment of wild-type or hereditary transthyretin amyloidosis
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Advice on a potential candidate for conditional inclusion of ataluren (Translarna®) for Duchenne's muscular dystrophy
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice concerning siponimod (Mayzent®) for the treatment of secondary progressive multiple sclerosis
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice venetoclax (Venclyxto®) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of ozanimod (Zeposia®) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of amisulpride (Aktiprol®) for the treatment of schizophrenia
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice esketamine nasal spray (Spravato®) for the treatment of adults with treatment-resistant major depressive disorder
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Atectura® Breezhaler® (indacaterol acetate/mometasone furoate)